drugset / Trial / NCT06174298

The Role of Granulocyte Colony Stimulating Factor in Embryo Transfer Outcomes

NCT06174298

Phase 4 Unknown 300 enrolled Newlife Fertility Centre
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this clinical trial is to test the effect of granulocyte colony-stimulating factor (G-CSF, A.K.A. Filgrastim) in infertility patients undergoing in vitro fertilization (IVF) treatment. The main question it aims to answer is: Can in vitro fertilization-embryo transfer (IVF-ET) outcomes be improved by supplementing the transfer media with Granulocyte colony-stimulating factor (GCSF)? Participants will undergo their embryo transfer as per the normal clinic protocol but will be randomized to either receive the standard embryo transfer media or the GCSG-supplemented transfer media. Researchers will compare the GCSF and standard transfer media groups to see if clinical outcomes are improved (i.e., implantation rate, pregnancy, clinical pregnancy rate, live birth rate).

Timeline

Start
2024-03-20
Primary completion
2025-01-10
Completion
2025-01-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject filgrastim Protein / enzyme biologic